Abstract
Enalapril is used to treat hypertension and congestive heart failure in infants. However, enalapril is not labeled for neonates, and safety data in infants are sparse. To evaluate the safety of enalapril in young infants, we conducted a retrospective cohort study of infants who were exposed to enalapril in the first 120 days of life and were cared for in 348 neonatal intensive care units from 1997 to 2012. We determined the proportion of exposed infants who developed adverse events, including death, hypotension requiring pressors, hyperkalemia, and elevated serum creatinine. Using multivariable logistic regression, we examined risk factors for adverse events, including postnatal age at first exposure, exposure duration, gestational age group, small for gestational age status, race, sex, 5-min Apgar score, and inborn status. Of a cohort of 887,910 infants, 662 infants (0.07%) were exposed to enalapril. Among exposed infants, 142 infants (21%) suffered an adverse event. The most common adverse event was hyperkalemia (13%), followed by elevated serum creatinine (5%), hypotension (4%), and death (0.5%). Significant risk factors for adverse events included postnatal age <30 days at first exposure and longer exposure duration. This study is the largest to date examining the safety of enalapril in young term and preterm infants without significant structural cardiac disease.
Similar content being viewed by others
References
Dutertre JP, Billaud EM, Autret E, Chantepie A, Oliver I, Laugier J (1993) Inhibition of angiotensin converting enzyme with enalapril maleate in infants with congestive heart failure. Br J Clin Pharmacol 35:528–530
Frenneaux M, Stewart RA, Newman CM, Hallidie-Smith KA (1989) Enalapril for severe heart failure in infancy. Arch Dis Child 64:219–223
Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA (1991) Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 78:128–135
Mason T, Polak M, Pyles L, Mullett M, Swanke C (1992) Treatment of neonatal renovascular hypertension with intravenous enalapril. Am J Perinatol 9:254–257
BTA Pharmaceuticals, Inc. VASOTEC (enalapril maleate) tablet [updated June 2010]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc
Blowey DL, Duda PJ, Stokes P, Hall M (2011) Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens 5:478–483
Dionne JM, Abitbol CL, Flynn JT (2012) Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol 27:17–32
Singh HP, Hurley RM, Myers TF (1992) Neonatal hypertension. Incidence and risk factors. Am J Hypertens 5:51–55
Hsu DT, Zak V, Mahony L, Sleeper LA, Atz AM, Levine JC et al (2010) Enalapril in infants with single ventricle results of a multicenter randomized trial. Circulation 122:333–340
Lindle KA, Dinh K, Moffett BS, Kyle WB, Montgomery NM, Denfield SD et al (2014) Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatr Cardiol 35:499–506
Bianchetti MG, Caflisch M, Oetliker OH (1992) Cough and converting enzyme inhibitors. Eur J Pediatr 151:225–226
Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA (2000) Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr Nephrol 14:1088–1091
Hom KA, Hirsch R, Elluru RG (2012) Antihypertensive drug-induced angioedema causing upper airway obstruction in children. Int J Pediatr Otorhinolaryngol 76:14–19
Meyers RS, Siu A (2011) Pharmacotherapy review of chronic pediatric hypertension. Clin Ther 33:1331–1356
Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A et al (2011) Efficacy and safety of valsartan compared to enalapril in hypertensive children. J Hypertens 29:2484–2490
Webb NJA, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP et al (2012) Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 82:819–826
Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P et al (2002) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 42:870–880
Testoni D, Hayashi M, Cohen-Wolkowiez M, Benjamin DK Jr, Lopes RD, Clark RH et al (2014) Late-onset bloodstream infections in hospitalized term infants. Pediatr Infect Dis J 33:920–923
Linhart Y, Bashiri A, Maymon E, Shoham-Vardi I, Furman B, Vardi H et al (2000) Congenital anomalies are an independent risk factor for neonatal morbidity and perinatal mortality in preterm birth. Eur J Obstet Gynecol Reprod Biol 90:43–49
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104:1985–1991
Raebel MA (2012) Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 30:e156–e166
Fanos V, Dessi A, Puddu M, Ottonello G (2014) Perinatal asphyxia and kidney development. In: Faa G, Fanos V (eds) Kidney development in renal pathology. Springer, New York, pp 59–66
Lorenz JM, Kleinman LI, Ahmed G, Markarian K (1995) Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics 96:484–489
Nakamura H, Ishii M, Sugimura T, Chiba K, Kato H, Ishizaki T (1994) The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Clin Pharm Ther 56:160–168
Guron G, Friberg P (2000) An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 18:123–137
Ku LC, Smith PB (2015) Dosing in neonates: special considerations in physiology and trial design. Pediatr Res 77:2–9
Filler G, Wong H, Condello AS, Charbonneau C, Sinclair B, Kovesi T et al (2003) Early dialysis in a neonate with intrauterine lisinopril exposure. Arch Dis Child Fetal Neonatal Ed 88:F154–F156
Murki S, Kumar P, Dutta S, Narang A (2005) Fatal neonatal renal failure due to maternal enalapril ingestion. J Matern Fetal Neonatal Med 17:235–237
Schubiger G, Flury G, Nussberger J (1988) Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med 108:215–216
Ratnapalan S, Koren G (2002) Taking ACE inhibitors during pregnancy. Is it safe? Can Fam Physician 48:1047–1049
Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA (2003) Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 12:633–646
Guron G, Molne J, Swerkersson S, Friberg P, Hansson S (2006) A 14-year-old girl with renal abnormalities after brief intrauterine exposure to enalapril during late gestation. Nephrol Dial Transplant 21:522–525
Schilder J, Van den Anker J (1995) Use of enalapril in neonatal hypertension. Acta Paediatr 84:1426–1428
Wells TG, Bunchman TE, Kearns GL (1990) Treatment of neonatal hypertension with enalaprilat. J Pediatr 117:664–667
Dutta S, Narang A (2003) Enalapril-induced acute renal failure in a newborn infant. Pediatr Nephrol 18:570–572
Russo A, Mirani A, Perlman J, Miller S (2013) Enalapril-induced acute kidney injury in neonates. J Neonatal Perinatal Med 6:179–181
Zimmerman KO, Hornik CP, Ku L, Watt K, Laughon MM, Bidegain M et al (2015) Sedatives and analgesics given to infants in neonatal intensive care units at the end of life. J Pediatr 167:299e3–304e3
Laughon MM, Chantala K, Aliaga S, Herring AH, Hornik CP, Hughes R et al (2015) Diuretic exposure in premature infants from 1997 to 2011. Am J Perinatol 32:49–56
Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH et al (2015) Safety of octreotide in hospitalized infants. Early Hum Dev 91:387–392
Chu PY, Hill KD, Clark RH, Smith PB, Hornik CP (2015) Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database. Early Hum Dev 91:345–350
Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB et al (2014) Medication use in the neonatal intensive care unit. Am J Perinatol 31:811–821
Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM et al (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131:350–355
Acknowledgements
The Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Daniel K. Benjamin Jr., MD, PhD, Katherine Y. Berezny, BSMT, MPH, Michael Cohen-Wolkowiez, MD, PhD, Duke Clinical Research Institute, Durham, NC; Gregory L. Kearns, PharmD, PhD, Arkansas Children’s Hospital, Little Rock, AR; Matthew M. Laughon, MD, MPH, University of North Carolina, Chapel Hill, NC; Ian M. Paul, MD, MSc, Penn State College of Medicine, Hershey, PA; Michael J. Smith, MD, MSCE, University of Louisville, Louisville, KY; John van den Anker, MD, PhD, George Washington University School of Medicine and Health, Washington, DC; Kelly Wade, MD, Children’s Hospital of Philadelphia, Philadelphia, PA.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development
David Siegel, MD, Perdita Taylor-Zapata, MD, Anne Zajicek, PharmD, Zhaoxia Ren, MD, PhD, Ekaterini Tsilou, MD, Alice Pagan, BBA.
The EMMES Corporation (Data Coordinating Center)
Ravinder Anand, PhD, Traci Clemons, PhD, Gina Simone, BS.
Funding
Dr. Ku receives research support from the National Institute of Child Health and Human Development (5T32GM086330-03, 5T32HD043029-13, and 4K12HD043494-14). Dr. Zimmerman receives research support from the Duke Clinical and Translational Science Awards (KL2TR001115-03). Dr. Hornik receives research support for research from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) (UL1TR001117). Dr. Smith receives salary support for research from the NIH and the National Center for Advancing Translational Sciences of the NIH (UL1TR001117), the National Institute of Child Health and Human Development (HHSN275201000003I and 1R01-HD081044-01) and the Food and Drug Administration (1R18-FD005292-01); he also receives research support from Cempra Pharmaceuticals (subaward to HHS0100201300009C) and industry for neonatal and pediatric drug development (www.dcri.duke.edu/research/coi.jsp). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr. Benjamin and Dr. Clark have nothing to disclose.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
For this type of study, formal consent is not required. Approval for this study was obtained from the Duke University Institutional Review Board.
Rights and permissions
About this article
Cite this article
Ku, L.C., Zimmerman, K., Benjamin, D.K. et al. Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. Pediatr Cardiol 38, 155–161 (2017). https://doi.org/10.1007/s00246-016-1496-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-016-1496-2